CLS Q2 2023: In the right direction - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

CLS Q2 2023: In the right direction - Redeye

{newsItem.title}

Redeye provides an update in relation to CLS’ Q2 2023 report. The results fairly aligned with our expectations, with sales of SEK1.3m (SEK0.4m) and an EBIT of SEK-17.0m (SEK-18.7m). We argue the company’s outlook is better than it has been in many years and look forward to the rest of 2023. We have only made minor estimate changes based on last week’s report. The changes do not render any changes in our fair value range, including a base case of SEK0.4.

Länk till analysen i sin helhet: https://www.redeye.se/research/939237/cls-q2-2023-in-the-right-direction?utm_source=finwire&utm_medium=RSS

Nyheter om Clinical Laserthermia

Läses av andra just nu

Om aktien Clinical Laserthermia

Senaste nytt